Mark R. Exchangers, President and Chief Executive Officer of PLC Systems, said: We are very delighted Renal Guard presented this important audience, and especially pleased that Dr. Escaned demonstrating a live case illustrates how Renal Guard and how it benefits for patients køb online . CIN is a significant and growing concern worldwide, and we are very excited about the prospect of Renal Guard to fix it encouraged. .
About PLC Systems Inc.PLC Systems Inc. Is a medical technology company specializing in innovative technologies for the cardiac and vascular markets. Based in Franklin, For this purpose, the. CO2 Heart Laser System, which cardiac surgeons use to perform CO2 transmyocardial revascularization symptoms of severe symptoms of severe angina pectoris PLC ‘s newest product, Renal Guard is approved for sale in the EU as a general fluid balancing device. This press release contains forward-looking statements . For this purpose, any statements contained in this release forward-looking statements refer to future events or developments are forward-looking statements be. Words such as believes, expects, plans, expects, will and similar expressions are intended to identify forward-looking statements. Our statements of our objectives are also forward-looking statements. While we can choose -looking statements-looking statements in the future, we specifically disclaim any obligation to do so, also change if our estimates, and you should not rely on these forward-looking statements as a representative of our views at any time after the date of this news release. In such forward differ materially from those in such forward – looking statements as result of a variety of factors, including that to market , we may not be necessary regulatory approvals for our Renal Guard product or that such approvals may be withdrawn, we can not specify in a position sufficient resources to increase in the future to make our business to perform plan and / or commence our planned U.S. Clinical trial for renal Guard, the current clinical trial in Italy and the planned future U.S. Clinical trial for renal Guard as a safe and effective prevention of contrast-induced nephropathy may not be be completed on time, if at all, if these clinical trials are completed, they may not produce clinically significant or meaningful results, the Renal Guard product commercially commercially, can operational changes, competitive developments affecting the market for our products, may may 31st the market for our products, and additional risk factors in the Forward Looking Statements section in our Annual Report on Form 10-K for the year ended December 2008 influence described, and our other SEC reports.
With their children. Have little effect on the capacity of people Contextually find and FAMILLE.
Gave A new study by Jasmohan Bajaj and colleagues in Virginia Commonwealth University and McGuire VA Medical Center that patients liver cirrhosis who designed minimal hepatic encephalopathy had a 16 percent rate of the compared with merely 4 percent of patients without a MHE over a year. The rate of injuries was also significantly higher than the state publishes an annual crash of 3 percent-3, the results of the study were published in of the October issue of Hepatology, a journal of Wiley-Blackwell on behalf of American Association Study of the Liver.